Replies to post #211726 on Biotech Values

[rkrw]

Keep in mind if they raise a lot of money, here, with the stock at a buck, I can only guess how bad the terms will be. It's not easy or common to dig out of those kinds of holes.

[DewDiligence]

EPIX -48%/PM on termination of EPI-506 program:

https://finance.yahoo.com/news/essa-pharma-announces-results-phase-113000355.html

EPI-506 was generally well-tolerated with a favorable safety profile across all doses up to 2400 mg. At a dose of 3600 mg, gastrointestinal adverse events (nausea, vomiting, abdominal pain) were observed in two patients: one patient in the once-daily ("QD") dosing cohort and one patient in the 1800 mg twice-daily dosing cohort, leading to study discontinuation and dose-limiting toxicity ("DLT") due to >25% missed doses in the 28-day safety reporting period. A separate patient in the 3600 mg QD cohort experienced a transient Grade 3 increase in liver enzymes (AST/ALT), which also constitutes a DLT, so enrollment was concluded in that cohort.

The unuasually high doses mentioned in prior posts on this board were telling.